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FK 506 Salvage of Renal Allografts With Ongoing Rejection Failing 
Cyclosporine Immunosuppression 
M.L. Jordan, R. Shapiro, C.A. Vivas, V.P. Scantlebury, F.S. Darras, G. Carrieri, J. McCauley, A.J. Demetris, 
P. Randhawa, C. Jensen, T.R. Hakala, J.J. Fung, and T.E. Starzl 
FK 506 is an experimental immunosuppressive drug that has been used with encouraging results as pri-
mary therapy in early clinical trials of renal transplanta-
tion. 1•2 In an early randomized trial comparing FK 506 and 
cyclosporine (CyA)-based immunosuppression, the major 
advantage of FK 506 appeared to be the ability to taper 
steroids, permitting FK 506 monotherapy, with no addi-
tional risk ofrejection episodes in 60% of patients. 2 This is 
usually not possible with CyA-based immunosuppression 
because of both increased risk of rejection and nephrotox-
icity.3 The superior results observed with FK 506 may be 
due in part to its greater immunosuppressive potency 
compared to Cy A. 4 These observations led us to evaluate 
FK 506 as a salvage agent to "rescue" renal allografts 
failing CyA-based therapy. We previously reported that 
FK 506 is unlikely to salvage renal allografts with chronic 
rejection or CyA toxicity.s However, conversion from 
Cy A to FK 506 in failing grafts with ongoing acute rejec-
tion appeared to be much more promising, with graft 
salvage in 17 of 24 (71%) such cases.s We report herein our 
expanded experience with FK 506 conversion as "rescue" 
therapy for renal allografts with ongoing rejection failing 
Cy A therapy. 
MATERIALS AND METHODS 
Patients 
A total of 54 patients (30 male. 24 female) with a mean age of 33.7 
~ 10.9 years (range 8 to 59 years) were failing CyA immunosup-
pression and were converted to FK 506. Forty-three patients had 
undergone primary transplantation and II had been retrans-
planted (8 second. 2 third. and I fourth transplants). Thirty-five 
were recipients of cadaveric (CAD) grafts and 19 were from living 
donors (15 related, 4 nonrelated). 
Evaluation for FK 506 Conversion 
All S4 patients considered for conversion to FK 506 had uncon-
trolled rejection on primary CyA-based immunosuppression. For-
ty-one patients (76%) were referred to us from other centers 
where they were deemed to be losing their grafts; 13 patients 
(24%) were entered from our own institution. Prior to FK 506 
conversion. maintenance immunosuppression consisted of CyA 
and prednisone in all patients. either with (n = 37) or without (n = 
17) azathioprine (AZA). Previous treatment for rejection had been 
administered to all 54 patients in the form of bolus high-dose 
steroids; 37 patients (69%) had also received one (n = 28) or two 
(n = 9) courses of OKT3 prior to conversion. Fifteen patients 
(28%) received both OKT3 and antilymphocyte globulin (ALG) 
prior to FK 506. 
All patients were evaluated by Doppler ultrasound and radio-
nuclide ftow study of the allograft to rule out a technical cause of 
allograft dysfunction prior to conversion. Core biopsies of the 
allograft were performed in all patients and revealed acute cellular 
rejection (ACR) in all cases; 13 of the biopsies also showed 
components of vascular rejection. 
Procedure for FK 506 Conversion 
All 54 patients had received Cy A doses maximized to tolerable 
levels. A simple switch ("clean conversion") from Cy A to FK 506 
was carried out in all cases by giving a standard daily oral dose of 
0.3 mg/kgld FK 506 in divided doses every 12 hours starting 12 
hours after the last CyA dose. In addition. 14 patients received 
parenteral doses of FK 506 of 0.025 to 0.1 mg/kgld overlapping 
with the first I to 4 days of oral therapy. Dose adjustments were 
based upon monitoring of trough serum FK 506 levels by ELISA 6 
to achieve a 12-hour trough level of 1.0 to 2.0 ng/mL. and also by 
adjustment according to clinical and biochemical parameters. 
Data were analyzed for statistical significance by Student's t test 
and chi-square analysis where appropriate. 
RESULTS 
FK 506 conversion was deemed successful contingent 
upon a return to baseline serum creatinine (SCr), andlor 
improvement on postconversion renal allograft biopsy, 
andlor freedom from dialysis if the patient was dialysis 
dependent at conversion. With a mean follow-up of 10.6 ± 
7.3 months, success was achieved in 38 of 54 patients 
(70%) switched to FK 506 based on these criteria (Table 1). 
Of these, 9 patients (24%) had evidence of a vascular 
component of rejection on preconversion biopsy. Thirty-
seven patients had failed at least one course of OKT3 
(average length of treatment 11 days) and, of these, 15 had 
Table 1. FK 506 Conversion In 54 Renal Transplant Recipients 
Failing CyA Therapy 
Indication for FK 506 No. Successful 
Conversion No. Patients (%) Conversions (%) 
Acute cellular rejection 34 (63%) 26(76%) 
Vascular rejection 13 (24%) 9(69%) 
Acute cellular rejection with 7 (13%) 3(43%) 
primary graft nonfunction 
Total 54 38 (70%) 
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also received induction ALG. In sum. of 38 patients 
receiving preconversion antilymphocyte preparations. 28 
(74%) were salvaged with FK 506. Fifteen patients (28%) 
were already dialysis dependent prior to conversion to FK 
506. Eight of these patients (53%) now have functioning 
grafts with a mean SCr of 1.86 ± 0.53 (mean follow-up IS 
± 8.3 months postconversion). 
The median time to rescue with FK S06 for all S4 
patients was 2 months (range 2 weeks to 36 months) after 
transplantation. In those patients successfully rescued, the 
mean SCr prior to FK S06 (excluding the eight patients on 
dialysis at conversion) was 3.3 ± 1.6 mg/dL which fell after 
FK 506 therapy to a mean of 2.4 ± 0.7 mg/dL (P < .OS). 
Including the eight patients on dialysis at the time of 
conversion. the average SCr after FK S06 conversion was 
2.3 ± 0.7 mg/dL. Salvage of cadaveric grafts (24 of 3S. 
69%) and grafts from living donors (14 of 19. 74%) was 
achieved with equal frequency. Those patients initially 
immunosuppressed with CyA. prednisone. and AZA (n = 
37) experienced a superior success rate of 81 % compared 
with 47% for those who had received Cy A and prednisone 
alone (n = 17) preconversion (P < .01). Of 41 patients 
referred from other centers for FK S06 conversion, 31 
(76%) were successfully rescued compared with 7 of 13 
(S4%) successes in patients from our own institution. Of 
the 43 primary transplantations. 30 (70%) were success-
fully converted; 8 of the 11 retransplants (73%) were 
successes. Four patients with kidney-pancreas transplants 
were converted with 3 successes (75%). Three patients 
undergoing FK S06 conversion had been transplanted with 
pediatric en bloc kidneys; 2 (67%) were successfully sal-
vaged. 
Morbidity and Mortality 
There were five deaths, all occurring in patients whose 
grafts had been lost. Two patients died from overwhelming 
sepsis and lymphoma at I month and 7 months postcon-
version, respectively. One patient died 8 months after 
conversion while on dialysis (etiology unknown), 1 from 
overwhelming sepsis at 1 month, and I patient succumbed 
to an intracranial hemorrhage 4 months after conversion. 
Eleven patients referred for FK S06 rescue had experi-
enced prior complications including CMV gastritis in 4, 
urine leak requiring surgical correction in 3. perforated 
duodenal ulcer following high-dose steroid therapy for 
rejection in I, ureteral obstruction in I, herpesvirus infec-
tion (cutaneous) in I, and Candida esophagitis in l. Eight 
of these patients (73%) were subsequently successfully 
rescued with FK S06. There were 9 complications follow-
ing FK S06 conversion including new onset diabetes mel-
litus in 2 patients (1 requiring insulin, 1 controlled on oral 
medication), epistaxis (n = 1), cecal perforation (n = 1). 
line sepsis (n = I). disease recurrence (membranoprolifer-
ative glomerulonephritis. n = I). proteinuria (n = I), and 
bacterial pneumonia (n = 1). None of these complications 
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Table 2. Steroid Therapy Before and After FK 506 Rescue 
Prednisone 
No" Patients (%) 
Dose (mg/d) Preconversion Postconversion 
0 0(0%) 6 (16%) 
5 0(0%) 5 (13%) 
H 0(0%) 6 (16%) 
10 5 (13%) 13 (34%) 
12.5 1 (2.5%) 3 (8%) 
15 1 (2.5%) 2 (5%) 
20 21 (55%) 2 (5%) 
>20 10 (27%) 1 (3%) 
Mean dose 21.3 ± 7.5 8.8 ± 6.2 
could be directly related to FK 506 therapy and none 
resulted in mortality. 
Immunosuppression and Biochemistry Following FK 506 
ConverSion 
All patients successfully converted from Cy A to FK S06 
were taking prednisone prior to conversion (Table 2). 
Prednisone doses have been lowered from an average of 
21.3 ± 7.S mg/d preconversion to 8.8 ± 6.2 mg/d postcon-
version, and 6 patients (16%) are currently on FK 506 
monotherapy. Mean cholesterol and triglycerides were 193 
± 28.S and 221.8 ± 97.6 mg/dL preconversion and 181.2 ± 
33.6 and 193.5 ± 96.8 mg/dL postconversion, respectively 
(P = NS). In nondiabetics. glucose was 9S.5 ± 16.7 mg/dL 
preconversion and 91.2 ± IS.7 postconversion (P = NS). 
Serum uric acid was 7.2 ± 2.3 mg/dL and 7.0 ± 2.1 (P = 
NS), respectively. 
DISCUSSION 
Since the advent of CyA-based immunosuppression. the 
results of renal transplantation have improved marked-
ly.7-9 Unfortunately, the incidence of rejection episodes 
remains high even with mUltiple drug regimens based on 
Cy A. 3 Treatment of persistent rejection with high-dose 
steroids and/or antilymphocyte preparations have until 
now been the only options open to the clinician faced with 
a failing graft under Cy A-based therapy. These treatment 
strategies are not always successful and. of themselves, 
have high attendant morbidity. An alternative treatment 
for persistent graft rejection would be an important addi-
tion to the armamentarium of the transplant physician. FK 
506 has shown great promise as a primary therapeutic drug 
in renal transplantation. and its use permits withdrawal of 
steroids in up to 60% of patients. This study illustrates 
another. perhaps even more important use for FK S06 as a 
therapeutic tool. In 38 of S4 (70%) patients losing their 
grafts to ongoing rejection, rescue therapy with FK S06 
resulted in graft salvage. Twenty-eight of these 38 patients 
(74%) had already failed treatment with antilymphocyte 
preparations and all had previously received high-dose 
steroid therapy. Graft salvage by conversion to FK S06 
was achieved with little, if any, morbidity. Steroid tapering 
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was still possible in the majority of patients successfully 
switched to FK 506, and no patient required subsequent 
treatment for recurrent rejection. Six patients have been 
taken off prednisone completely. Necessity for dialysis 
was not a preclusion for conversion to FK 506, as 8 of 15 
such patients achieved graft function (mean SCr 1.9) 
following rescue. 
The precise mechanisms by which FK 506 affects graft 
salvage as an "antirejection" agent is unclear. Another 
novel drug, RS-61443, has recently been reported to show 
promise in reversing ongoing rejection,1O although with 
somewhat less success than that reported herein with FK 
506. As alternative strategies to the more traditional meth-
ods of treating recalcitrant rejection are developed, im-
proved long-term graft survival and reduced patient mor-
bidity will hopefully be observed. The use of FK 506 to 
salvage renal allografts with ongoing rejection after failed 
CyA therapy appears to be a safe and effective means to 
help achieve these goals. 
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